The Phase III study FIND-CKD, evaluating the efficacy and safety of finerenone (Kerendia) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney… read more.
Eli Lilly and Company announced that access to self-pay pricing on the new Zepbound (tirzepatide) KwikPen for single-patient use will be available at LillyDirect and major pharmacies nationwide,… read more.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it will present… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has approved imlunestrant tosylate (Inluriyo), a new treatment for adult patients with a certain type of breast… read more.
The company’s partner, Jazz Pharmaceuticals, will present four abstracts featuring data from clinical trials evaluating Ziiher (zanidatamab-hrii) at the American Association for Cancer Research (AACR) Annual Meeting, being… read more.
NICE(UK): Dupilumab, as an add-on to intranasal corticosteroids, can be used as an option to treat severe chronic rhinosinusitis with nasal polyps in adults if: i) the condition… read more.
The company and its research collaborators will present 28 abstracts, including 3 oral sessions, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Association… read more.
Bristol Myers Squibb announced that the FDA has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA). Sotyktu, an oral, selective tyrosine kinase 2… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved deuruxolitinib (Leqselvi) from Sun Pharma UK Ltd. to treat severe alopecia areata in adults. Approval was based on… read more.
The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a positive opinion, recommending the granting of a marketing authorisation for Poherdy in combination with trastuzumab and… read more.
Vertex Pharmaceuticals Incorporated announced data from a Phase IV study of Journavx (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults,… read more.
GE HealthCare announced that View has received 510(k) clearance from the FDA. Designed as a fast, diagnostic, zero‑footprint viewer, View serves as the core anchor of the Genesis… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
